Lycia Therapeutics
An October 2026 SEC filing reports preliminary human IgE reduction in Phase 1 for the IgE cataLYTAC LCA-0061. Phase 1 LCA-0321 in Graves' disease is ongoing; LCA-0062 is in IND preparation.
United StatesFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
74 matching companies
Avilar Therapeutics
A 2026-10-08 website announcement describes a preclinical sFlt1 ATAC for preeclampsia. ATAC uses ASGPR to route extracellular target proteins into hepatocyte lysosomes.
United StatesFull profile →
TRIMTECH Therapeutics
A 2026-06-23 announcement states that TRIM21 E3-associated TRIMTAC/TRIMGLUE selectively degrade toxic aggregates and oligomers while sparing functional monomers, in early portfolio development.
United KingdomFull profile →
SEED Therapeutics
The website and 2026 ASCO materials identify ST-01156 as an RBM39 molecular glue degrader in Phase 1 studies in solid tumors including Ewing sarcoma and hepatocellular carcinoma.
United StatesFull profile →
Proxygen
The website describes covalent p300 molecular glues and Cyclin K degradation-mediated CDK12 regulation. An April 2026 announcement advances two MGD pipelines toward development candidates and IND preparation while expanding nondegradative induced proximity.
AustriaFull profile →
TRIANA Biomedicines
A March 2026 announcement reports the first patient treated in Phase 1/2 TRI-611. A September 2026 Nature paper describes its distinctive ALK–CRBN interface and preclinical intracranial tumor models.
United StatesFull profile →
Biotheryx
A May 2026 announcement reports PK, PBMC degradation, and early activity in Phase 1 dose escalation of the bifunctional CDK4/6 degrader BTX-9341; expansion studies are ongoing.
United StatesFull profile →
Biohaven
A 2026-10-29 announcement reports Phase 3 BHV-1300 recruiting in Graves' disease and licensing of part of the Asian MoDE pan-IgG portfolio to Ono. Phase 3 BHV-1400 was still planned at that time.
United StatesFull profile →
Carrick Therapeutics
The website describes CT7439 as both a CDK12/13 inhibitor and Cyclin K glue degrader. Its Phase 1/2 trial, NCT06600789, uses oral capsules.
United States / 爱尔兰 / United KingdomFull profile →
Photys Therapeutics
An original 2026-08-13 Photys / Polymed announcement reports Phase 1 healthy-volunteer dosing of PHT-776/HPB-143. Photys holds rights outside Greater China and Southeast Asia.
United StatesFull profile →
Rigel Pharmaceuticals
A 2026-06-16 Rigel announcement confirms completion of an exclusive global development, manufacturing, and commercialization license for VEPPANU from Arvinas/Pfizer, effective 2026-06-11.
United StatesFull profile →
Frontier Medicines
An October 2025 company announcement and original structural study establish DCAF2 as an E3 for PROTAC-mediated degradation. This does not make the company's other clinical small molecules degraders.
United StatesFull profile →
Cullgen, a Gyre company
Gyre completed its acquisition of Cullgen on 2026-05-04; they are consolidated into one company record.
United States / ChinaFull profile →
Ranok Therapeutics
CHAMP-1 is a Phase 1/2 RNK05047 study. The study center's description specifies BRD4 clearance and intravenous administration.
China / United StatesFull profile →
Hinova Pharmaceuticals
The website identifies HP518 as an oral AR PROTAC. Enrollment in China Phase 2 is complete, Australian Phase 1 is complete, and China combination Phase 1/2 authorization was obtained in November 2025.
ChinaFull profile →
Degron Therapeutics
A May 2026 financing announcement describes DEG6498 as an oral HuR molecular glue inducing a CRBN–HuR interaction. First dosing occurred in November 2025; Phase 1 dose escalation is ongoing.
China / United StatesFull profile →
Ubix Therapeutics
The Degraducer website specifies bifunctional linkers and a ubiquitin–proteasome mechanism. Lead asset UBX-303-1 targets BTK.
South KoreaFull profile →
Pin Therapeutics
An original 2026 ASCO abstract describes PIN-5018 as an oral CRBN-mediated CK1α molecular glue. The first Phase 1 cohort completed without DLTs; subsequent cohorts are enrolling.
South KoreaFull profile →
SK Life Science Labs
The website lists a selective heterobifunctional p300 degrader as IND-enabling. PVTX-321 ER and PVTX-405 IKZF2 molecular glues are ready for GLP toxicology scale-up.
United States / South KoreaFull profile →
FIMECS
A July 2026 patent announcement explicitly identifies FIM-001 as an IRAK-M degrader still in preclinical development.
JapanFull profile →
GluBio Therapeutics
The website lists GLB-001 Phase 1 in U.S. AML/HR-MDS and Chinese myeloid tumors, and GLB-002 Phase 1 in Chinese NHL.
United States / ChinaFull profile →
BeOne Medicines (formerly BeiGene)
The website lists CaDAnCe-302 for tacabrutideg/BGB-16673 as Phase 3. CDAC is the company's term for chimeric degradation-activating compounds.
China / United States / SwitzerlandFull profile →
Kintor Pharmaceutical
GT20029 is a topical AR PROTAC. A 2024 announcement reports that the China Phase 2 male androgenetic alopecia study met its primary endpoint.
ChinaFull profile →
Qilu Pharmaceutical
An original 2025 ESMO abstract describes QLH12016 as an oral AR PROTAC, with data through February 2025 from 36 patients with mCRPC.
ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.